Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pruvanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.98 |
| ▸ | HTR2C | P28335 | 4/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | HTR1D | P28221 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pruvanserin SCHEMBL29489913 | 1.00 | HTR2A (0.98) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL678751 | 0.99 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL9104227 | 0.99 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL29379046 | 0.99 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL3902103 | 0.95 | HTR2A (0.93) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL3914362 | 0.95 | HTR2A (0.93) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL6110393 | 0.90 | HTR2A (0.84) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL5280317 | 0.90 | HTR2A (0.84) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL6112038 | 0.90 | HTR2A (0.83) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Hydrochloric Acid SCHEMBL27520162 | 0.87 | HTR2A (0.98) | HTR2AHTR2CDRD4SLC6A2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101027284-B | Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride | MERCK PATENT GMBH | 2010-09-29 | — | — | CN | claimed |
| CN-101027284-A | Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)-piperazine-1-yl]-methanone hydrochloride | MERCK PATENT GMBH (DE) | 2007-08-29 | — | — | CN | claimed |
| EP-2288345-B1 | PSYCHO-PHARMACEUTICALS | UNIV DUBLIN (IE) | 2015-06-10 | — | — | EP | disclosed |
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| CN-101558057-B | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF | 2013-05-01 | — | — | CN | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006034774-A1 | NOVEL CRYSTALLINE FORM OF (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)-PIPERAZINE-1-YL]-METHANONE HYDROCHLORIDE | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | WO | disclosed |
| CN-1229345-C | N-(indolcarbonyl) piperazin derivatives | MERCK PATENT GMBH (DE) | 2005-11-30 | — | — | CN | disclosed |
| CN-1213029-C | Process for the preparation of (3-cyano-1H-indol-7-yl) (4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof | MERCH PATENT GMBH (DE) | 2005-08-03 | — | — | CN | disclosed |
| CN-1487923-A | Process for the preparation of (3-cyano-1H-indol-7-yl) (4- (4-fluorophenethyl) piperazin-1-yl) -methanone and salts thereof | Ĭ��ר���ɷ�����˾ | 2004-04-07 | — | — | CN | disclosed |
| CN-1364157-A | N-(indolcarbonyl) piperazin derivatives | MERCK PATENT GMBH (DE) | 2002-08-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR2A 406/4885HTR2C 660/4885DRD4 1926/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR2A 3184/4885HTR2C 3530/4885DRD4 4415/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | HTR2A 1201/4885HTR2C 1631/4885DRD4 1701/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR2A 406/4885HTR2C 660/4885DRD4 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.